Samsara Vision has launched a clinical trial in Europe to evaluate the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT) in pseudophakic patients with late-stage age-related macular degeneration (AMD). The first procedure was performed on September 30, 2025, by Dr. John Conrath, a vitreoretinal and cataract surgeon at Centre Monticelli-Paradis in Marseille, France.

PERSPECTIVE is a multicenter, randomized trial being conducted in France, Germany, and Italy, where the SING IMT is approved. It focuses on patients who previously underwent cataract surgery with an intraocular lens (IOL), a population previously ineligible for telescope implantation. Participants will receive structured visual rehabilitation alongside the implant to assess improvements in functional vision. The study, which is expected to enroll participants through 2026, will evaluate safety, visual outcomes, patient selection criteria, and rehabilitation strategies. The study may support future label expansion, potentially broadening access to the SING IMT in CE-referenced countries.

The SING IMT is currently being evaluated in the US-based CONCERTO trial for age 65 and older with late-stage AMD.